Skip to content

Cannabis: all studies

Page 141 of 288: studies 1,401 to 1,410 of 2,878, newest first. Back to the cannabis overview

Research

Cannabis use disorders and age at onset of psychosis in 606 patients with first episode psychosis

European Psychiatry March 1, 2011 B. Schimmelmann, S. Kupferschmid, Philippe Conus et al.

Background: Age at onset of psychosis (AAO) may be younger in patients with cannabis use disorders (CUD) compared to those without CUD (NCUD). Most previous studies did not control for potential confounders, did not report effect sizes and included mostly adult patients from non-representative samples. Methods: Controlling for relevant confounders, differences in AAO between patients with and...

Effects of chronic, heavy cannabis use on executive functions.

Journal of Addiction Medicine March 2011 Rebecca D Crean, Susan F Tapert, Arpi Minassian et al.

This case describes the clinical course of a cannabis-dependent individual entering a 12-week abstinence-based research program. The case illustrates the effects of chronic, heavy cannabis use on executive functions at three time points: 1) 24 hours of abstinence; 2) 4 weeks of abstinence; and 3) 12 weeks of abstinence. It is followed by discussions by two clinical psychologists and a...

An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions.

Journal of Addiction Medicine March 2011 Rebecca D Crean, Natania A. Crane, Barbara J Mason

Cannabis use has been shown to impair cognitive functions on a number of levels-from basic motor coordination to more complex executive function tasks, such as the ability to plan, organize, solve problems, make decisions, remember, and control emotions and behavior. These deficits differ in severity depending on the quantity, recency, age of onset and duration of marijuana use. Understanding...

Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study

BMJ March 1, 2011 Rebecca Kuepper, Jim van Os, Roselind Lieb et al. 307 citations

OBJECTIVE: To determine whether use of cannabis in adolescence increases the risk for psychotic outcomes by affecting the incidence and persistence of subclinical expression of psychosis in the general population (that is, expression of psychosis below the level required for a clinical diagnosis). DESIGN: Analysis of data from a prospective population based cohort study in Germany (early...

Subjective and physiological effects after controlled Sativex and oral THC administration.

Clinical Pharmacology & Therapeutics March 2011 E L Karschner, William D Darwin, Robert P McMahon et al.

Sativex is a cannabis-plant extract delivering nearly 1:1 Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) by oromucosal spray. It has been suggested that CBD attenuates THC-induced tachycardia, anxiety, and euphoria. In this study, pharmacodynamic effects were compared over 10.5 h in nine cannabis smokers randomly assigned to receive placebo, 5 and 15 mg oral synthetic THC, and low (5.4...

Medial temporal structures and memory functions in adolescents with heavy cannabis use

Journal of Psychiatric Research February 5, 2011 M. Ashtari, B. Avants, L. Cyckowski et al.

Converging lines of evidence suggest an adverse effect of heavy cannabis use on adolescent brain development, particularly on the hippocampus. In this preliminary study, we compared hippocampal morphology in 14 “treatment-seeking” adolescents (aged 18-20) with a history of prior heavy-cannabis use (5.8 joints/day) after an average of 6.7 months of drug abstinence, and 14 demographically matched...

Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs.

Archives of General Psychiatry February 2011

Individual differences in cannabis sensitivity may be associated with genetic risk for psychotic disorder. To demonstrate and replicate, using 2 conceptually different genetic epidemiological designs, that (familial) liability to psychosis is associated with sensitivity to cannabis. Sibling-control and cross-sibling comparisons using samples of patients with a psychotic disorder (n = 1120),...

Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up.

Archives of General Psychiatry February 2011 Ruud van Winkel

Individual differences exist in sensitivity to the psychotomimetic effect of cannabis; the molecular genetic basis underlying differential sensitivity remains elusive. To investigate whether selected schizophrenia candidate single-nucleotide polymorphisms (SNPs) moderate effects of cannabis use. Interactions between recent cannabis use, determined by urinalysis results, and 152 SNPs in 42...

Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol).

Psychopharmacology February 2011 Marieke M Lansbergen, Glenn Dumont, Joop van Gerven et al.

Typical users of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") are polydrug users, combining MDMA with alcohol or cannabis [most active compound: delta-9-tetrahydrocannabinol (THC)]. The aim of the present study was to investigate whether co-administration of alcohol or THC with MDMA differentially affects ongoing electroencephalogram (EEG) oscillations compared to the administration of...

Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats.

Neuropharmacology 2011 Natalia Realini, Daniela Vigano', Cinzia Guidali et al.

We have recently shown that chronic THC administration in adolescent female rats induces subtle but lasting alterations in the emotional circuit ending in depressive-like behaviour at adulthood. Here we describe other relevant depressive-like symptoms present in these animals. Adult female rats pretreated with THC display passive coping strategy towards acute stressful situations as...